Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BASF explores opportunities to invest in Brazil
BASF is conducting feasibility study to assess the technical, commercial and economic viability of operating a world-scale complex in Brazil. Following the completion of feasibility study, which is
BASF is conducting feasibility study to assess the technical, commercial and economic viability of operating a world-scale complex in Brazil. Following the completion of feasibility study, which is
The new production facility will have an initial capacity of 20,000 metric tonnes per year, and will produce high-tech plastics – Durethan and Pocan. To produce Durethan and
This follows the positive opinion on the designation that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency adopted previously in the November 2010 COMP
The company’s lead drug candidate, GO-203-2c is currently being studied in a Phase I trial which aims to determine the safety and tolerability, and potential anti-tumor activity of
The trial aimed to determine the safety, efficacy, tolerability and pharmacokinetics of X-Excite in men on side by side study with Pfizer’s Viagra. Reportedly, the study evaluated total
RECALL-VAXTM is a method to immunize people to produce specific natural antibodies against the beta amyloid (Aß) protein before it causes irreversible damage by accumulating in the brains
Qualitix is a full service CRO based in Taipei, Taiwan and Shanghai, China, and engaged in clinical monitoring and site management services for multinational clinical trials. With this
The extended dose interval of Somatuline Depot 120mg of 6 to 8 weeks is expected to offer patients with acromegaly who are currently controlled on Somatuline Depot 60mg
The precise syringe delivery of Venus Bulk Fill will provide dentists with an easier, faster restorative solution that is more cost effective per restoration than the traditional incremental
Cross Country Healthcare net loss was $6m, compared to a net income of $398,000 for the same period in 2009. For the full year of 2010, the company